Patents by Inventor Gernot Kaber

Gernot Kaber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11840703
    Abstract: The disclosure provides methods and constructs for the stable production and isolation of biologically functional recombinant V3, a splice variant of the extracellular matrix proteoglycan versican, as well as the protein product and reagents for detecting the same. In one embodiment, the disclosure provides expression systems for expressing rV3. In one embodiment, the disclosure provides an expression system that properly N-glycosylates mammalian proteins, such as V3. In another embodiment, rV3 has been isolated and purified. In another embodiment, the disclosure provides a unique expression construct containing a ubiquitous chromatin opening element upstream of a strong promoter which drives expression of recombinant V3. In yet a further embodiment, the disclosure provides an isolated and purified recombinant V3 protein in amounts suitable for testing and use, and in pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: December 12, 2023
    Inventors: Thomas N. Wight, Mervyn J. Merrilees, Gernot Kaber, Ingrid A. Harten, Michael G. Kinsella
  • Publication number: 20220079966
    Abstract: Compositions for treating an autoimmune, inflammatory, fibrotic, or proliferative disease or disorder comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone-glucuronide. Methods for treating an autoimmune, inflammatory, fibrotic, or proliferative disease or disorder, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 17, 2022
    Inventors: Paul L. Bollyky, Nadine Nagy, Gernot Kaber
  • Publication number: 20210024954
    Abstract: The disclosure provides methods and constructs for the stable production and isolation of biologically functional recombinant V3, a splice variant of the extracellular matrix proteoglycan versican, as well as the protein product and reagents for detecting the same. In one embodiment, the disclosure provides expression systems for expressing rV3. In one embodiment, the disclosure provides an expression system that properly N-glycosylates mammalian proteins, such as V3. In another embodiment, rV3 has been isolated and purified. In another embodiment, the disclosure provides a unique expression construct containing a ubiquitous chromatin opening element upstream of a strong promoter which drives expression of recombinant V3. In yet a further embodiment, the disclosure provides an isolated and purified recombinant V3 protein in amounts suitable for testing and use, and in pharmaceutical compositions thereof.
    Type: Application
    Filed: June 30, 2020
    Publication date: January 28, 2021
    Inventors: Thomas N. Wight, Mervyn J. Merrilees, Gernot Kaber, Ingrid A. Harten, Michael G. Kinsella